A TRYPSIN-LIKE SERINE PROTEASE ACTIVITY ON ACTIVATED HUMAN B-CELLS AND VARIOUS B-CELL LINES

被引:14
作者
BIRO, A [1 ]
SARMAY, G [1 ]
ROZSNYAY, Z [1 ]
KLEIN, E [1 ]
GERGELY, J [1 ]
机构
[1] KAROLINSKA INST, DEPT TUMOR BIOL, S-10401 STOCKHOLM 60, SWEDEN
关键词
D O I
10.1002/eji.1830221013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have studied the trypsin-like serine protease activity of human tonsillar B lymphocytes. The lysate of the low-density, in vivo activated B cells as well as the lysate of cells stimulated with anti-human IgM F(ab')2 show elevated trypsin-like serine protease activity compared to the resting subset as monitored by the cleavage of Tos-Gly-Pro-Arg-pNA. The cleavage is sensitive to N-tosyl-L-lysyl-chloromethyl ketone and benzamidine but not to iodoacetamide. Experiments with intact cells give similar results. The finding that the intact cells hydrolyze the substrate, while their supernatant does not, suggests that the protease activity is cell membrane associated. It is possible that C3 is a substrate of the enzyme since the activated B cells cleave C3, whereas the resting B cells do not, and also C3 inhibits the enzyme-substrate reaction. In addition to the ex vivo B cells, we studied the serine protease activity of certain well-characterized B cell lines. The results show a correlation between the phenotype and the enzyme expression of the cell lines. BL41, an Epstein-Barr virus (EBV)-negative Burkitt lymphoma line, with a resting phenotype, has low activity, while its EBV genome-carrying convertants E95-A-BL41, E95-C-BL4 1, EHR-A-BL41 and BL41/95 that have the phenotype of activated B cells, have high proteolytic activity. The lymphoblastoid cell line WW-1-LCL which has the phenotype of an immunoblast, has the highest serine protease activity. On the basis of the above data, we suggest that a rather tight correlation exists between the degree of activation and the appearance of serine protease(s) on the surface of human B cells.
引用
收藏
页码:2547 / 2553
页数:7
相关论文
共 32 条
[21]   INTERACTION OF TARGET CELL-BOUND C3BI AND C3D WITH HUMAN-LYMPHOCYTE RECEPTORS - ENHANCEMENT OF ANTIBODY-MEDIATED CELLULAR CYTO-TOXICITY [J].
PERLMANN, H ;
PERLMANN, P ;
SCHREIBER, RD ;
MULLEREBERHARD, HJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 153 (06) :1592-1603
[22]  
POE M, 1988, J BIOL CHEM, V263, P13215
[23]   ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION BY STIMULATED LYMPHOCYTES-T .2. ELEVATION OF CYTOTOXIC POTENTIAL AGAINST COMPLEMENT RECEPTOR-CARRYING CELL-LINES [J].
RAMOS, OF ;
SARMAY, G ;
EGGERTSEN, G ;
NILSSON, B ;
KLEIN, E ;
GERGELY, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (07) :975-979
[24]   PAIRED EPSTEIN-BARR VIRUS-CARRYING LYMPHOMA AND LYMPHOBLASTOID CELL-LINES FROM BURKITTS-LYMPHOMA PATIENTS - COMPARATIVE SENSITIVITY TO NON-SPECIFIC AND TO ALLO-SPECIFIC CYTO-TOXIC RESPONSES INVITRO [J].
ROONEY, CM ;
RICKINSON, AB ;
MOSS, DJ ;
LENOIR, GM ;
EPSTEIN, MA .
INTERNATIONAL JOURNAL OF CANCER, 1984, 34 (03) :339-348
[25]   MEMBRANE COMPLEMENT RECEPTORS SPECIFIC FOR BOUND FRAGMENTS OF C-3 [J].
ROSS, GD ;
MEDOF, ME .
ADVANCES IN IMMUNOLOGY, 1985, 37 :217-267
[26]   ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION BY STIMULATED LYMPHOCYTES-T .1. BINDING OF C3-FRAGMENTS [J].
SARMAY, G ;
RAMOS, OF ;
KLEIN, E ;
KAI, C ;
GERGELY, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (07) :969-974
[27]   MODULATION OF TYPE-II FC-GAMMA RECEPTOR EXPRESSION ON ACTIVATED HUMAN LYMPHOCYTES-B [J].
SARMAY, G ;
ROZSNYAY, Z ;
SZABO, I ;
BIRO, A ;
GERGELY, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (03) :541-549
[28]   INTERLEUKIN-2 PRODUCTION BY HUMAN LYMPHOCYTES-T IDENTIFIED BY ANTIBODIES TO DIPEPTIDYL PEPTIDASE-IV [J].
SCHOLZ, W ;
MENTLEIN, R ;
HEYMANN, E ;
FELLER, AC ;
ULMER, AJ ;
FLAD, HD .
CELLULAR IMMUNOLOGY, 1985, 93 (01) :199-211
[29]   STRUCTURE AND SPECIFICITY OF COMPLEMENT RECEPTORS [J].
SIM, RB ;
MALHOTRA, V ;
DAY, AJ ;
ERDEI, A .
IMMUNOLOGY LETTERS, 1987, 14 (03) :183-190
[30]  
TORSTEINDOTTIR S, 1989, INT J CANCER, V443, P273